European Society for Medical Oncology (ESMO) Asia Congress 2022_Open Use
| Title | European Society for Medical Oncology (ESMO) Asia Congress 2022_Open Use |
|---|---|
| Description | NIVO + chemo did not show statistically significant improvement in PFS in pts with EGFR-mut mNSCLC after progression on EGFR TKIs; however, a trend of benefit was seen in pts with sensitizing EGFR mutations and in those with 1 prior line of EGFR TKI tx. No new safety signals were identified. |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Open-access |
| BioProject | PRJCA012509 |
| Release Date | 2022-12-02 |
| Submitter | Qi Zhang (qi.zhang@ppd.com) |
| Organization | Guangdong Provincial People's Hospital |
| Submission Date | 2022-10-14 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002064-01 | European Society for Medical Oncology (ESMO) Asia Congress 2022 | 1 | Biomarker Data | 101.3 KB | zip | 0 |